載入中
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
一般交易時段
US$3.04
+US$0.10 · +3.40%
盤中時間採用ET。市場資料可能有所延遲。
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
日內區間
目前US$3.04
52週區間
目前US$3.04
盤中時間採用ET。市場資料可能有所延遲。
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
日內區間
目前US$3.04
52週區間
目前US$3.04
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 11.93萬 USD | — | — | — | 11.88萬 USD |
| 毛利 | −11.93萬 USD | — | — | — | −11.88萬 USD |
| 研究與開發 | 366.87萬 USD | 288.2萬 USD | 479.45萬 USD | 1333.53萬 USD | 1794.71萬 USD |
| 銷售、一般及管理費用 | 424.28萬 USD | 413.28萬 USD | 442.82萬 USD | 503.55萬 USD | 573.43萬 USD |
| 營業費用 | 779.23萬 USD | 701.47萬 USD | 922.28萬 USD | 1837.08萬 USD | 2368.13萬 USD |
| 利息收入 | 2558 USD | 15.35萬 USD | 28.98萬 USD | 6.35萬 USD | 1.12萬 USD |
| 折舊和攤銷 | 11.93萬 USD | 18.6萬 USD | 18.35萬 USD | 11.82萬 USD | 11.88萬 USD |
| 營業利益 | −791.16萬 USD | −701.47萬 USD | −922.28萬 USD | −1837.08萬 USD | −2368.13萬 USD |
| 淨利 | −718.55萬 USD | −617萬 USD | −837.44萬 USD | −1754.89萬 USD | −1334.32萬 USD |
公司資料更新於 2026年10月13日。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
